Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on mental health treatments, announced that CEO Michael Halstead will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held September 14-16, 2026, in New York City, with the fireside chat webcast live on September 14 at 9 a.m. EDT. A replay will be available on the Events & Presentations page of the company's investor relations website.
The announcement comes as Helus Pharma advances its pipeline of novel serotonergic agonists (NSAs), synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD) and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder (GAD).
The company's focus on NSAs aims to address the large unmet need for individuals suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma intends to improve the treatment landscape by providing durable improvements in mental health. The company operates in Canada, the United States, the United Kingdom, and Ireland.
The participation of CEO Michael Halstead at this prominent investment conference signals the company's commitment to engaging with the investment community and sharing updates on its clinical programs. Investors and industry observers will have the opportunity to gain insights into the company's strategic direction and the potential impact of its therapies on the mental health treatment market.
For more information about Helus Pharma and its pipeline, visit Helus Pharma's website. The full press release is available at this link.
